Trial Profile
A Phase I/II Trial of Evaluating the Combination of MK-3475 and Stereotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Oct 2023 Status changed from suspended to completed.
- 30 Aug 2021 Planned End Date changed from 1 Jun 2021 to 1 May 2022.
- 30 Aug 2021 Planned primary completion date changed from 1 Jun 2021 to 1 May 2022.